Brief: Amneal And Shilpa Announce U.S. FDA Approval Of Boruzu™
Sept 5 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL AND SHILPA ANNOUNCE U.S. FDA APPROVAL OF BORUZU™,
THE
FIRST READY-TO-USE VERSION OF BORTEZOMIB FOR SUBCUTANEOUS
ADMINISTRATION
* AMNEAL PHARMACEUTICALS: BORUZU IS EXPECTED TO LAUNCH WITH
A
UNIQUE J-CODE IN Q2 OF 2025
Source text for Eikon: ID:nBw7lsZTca
Further company coverage: AMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary